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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of bilateral versus unilateral hearing aids in adults with a bilateral hearing impairment.
B A C K G R O U N D
Description of the condition
Acquired hearing loss is a common adult condition, affecting 16%
of the adult UK population aged 18 to 80 years. The incidence
increases markedly with age with 37% of those aged 61 to 70 years
and 60%of those aged 71 to 80 years having a bilateral hearing loss
(Davis 1989; Davis 1994). A review of the world epidemiology
literature in 2000 suggested that globally 360 million adults have
a ’disabling’ loss in the better ear (> 40 dB HL) (Mathers 2000).
In most people the hearing loss is sensorineural and due to the loss
of hair cells in both inner ears, as opposed to a conductive hearing
loss that is due to middle or external ear pathology (Browning
1992). In the majority of cases the loss of hair cells occurs with
ageing, leading to a bilateral ’age-related’ hearing loss that affects
both ears to the same degree (Davis 1989; Davis 1994). This is
not the case with conductive hearing loss where the pathology
often affects one or both ears to a different extent. Age-related
sensorineural hearing loss is often combined with a conductive
hearing loss (mixed hearing loss).
The level of disability caused by hearing loss is mainly determined
by the hearing in the better hearing ear as assessed by pure-tone
audiometry. From the audiogram the average of the thresholds of
detection at four frequencies (0.5 kHz, 1 kHz, 2 kHz and 4 kHz)
is calculated and compared with the adult categories of normal (0
to 20 dB HL), mild (21 to 40 dB HL), moderate (41 to 70 dB
HL), severe (71 to 95 dBHL) and profound (> 90 dBHL) (WHO
1991).
Middle ear surgery has a potential role in a very small proportion
of patients with a pure conductive impairment, which is most fre-
quently unilateral. Profound hearing loss can be managed with
cochlear implants. Mild, moderate and severe sensorineural hear-
ing loss is primarily managed with hearing aids. The fitting of
hearing aids constitutes the majority of the workload of audiology
departments with an estimated 10.8 million aids being sold each
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year, based on a survey ofmanufacturers of hearing aids (Kirkwood
2013). Forty-five per cent of these were sold in Europe, 29% in
America and 26% in the rest of the world. However, this figure
grossly underestimates the potential usage of hearing aids, as the
majority (80%) of adults aged 55 to 74 years who have a disabling
hearing loss do not use aids (McCormack 2013).
Description of the intervention
Hearing aids
In this review, all participants receive hearing aids as the main in-
tervention; the comparison is between one aid fitted to one specific
ear and the fitting of aids to both ears.
Hearing aids amplify the sound reaching the ear. They can be ei-
ther digital or analogue instruments. With either technology the
degree of amplification of the hearing aid complex can be pro-
grammed to suit the characteristics of the patient’s hearing loss as
assessed with a pure-tone audiogram. Aids can vary in where they
are positioned: in-the-canal, in-the-ear, behind-the-ear and body-
worn. Patient choice is one important factor that determineswhich
is used, but the degree of hearing impairment is another. Hear-
ing aids can also have features such as directional microphones,
which are helpful in face-to-face conversation. There is consid-
erable variation in patients’ listening requirements. Some require
amplification only when listening to the television, for example,
whilst others have multiple requirements such as the need to hear
in varying background noise and with multiple speakers.
Most patients with sensorineural hearing loss have a reduced dy-
namic range and many hearing aids incorporate compression sys-
tems. These can be adjusted so that soft sounds are audible with-
out loud sounds being uncomfortable. To date, however, hearing
aids cannot directly compensate for other things that usually ac-
company sensorineural hearing loss, such as a reduced ability to
distinguish different frequencies. This may restrict or limit their
benefit.
Hearing aids are thought to be most suitable for patients with a
pure tone average of ≥ 25 dB HL to 70 dB HL. When hearing
loss is greater than 70 dB HL, alternative options such as cochlear
implants may be more suitable.
The provision of hearing aids varies widely in different health
services and resource settings. In some places hearing aids (either
one or two) are provided ’free’ to the patient, funded by the local
health care providers. In others, aids are only available to those
who can pay for them. In both systems there are cost implications
when two aids are provided rather than one.
When two aids are being considered, there are at least two alter-
native approaches:
• fit one aid then consider an aid for the other ear later;
• fit two aids from the beginning and leave it to the patient to
use two, one or no aids.
Thosewhouse hearing aids - or their carers - need sufficientmanual
dexterity to position the aid in the ear, to switch it on, to maintain
it (for example, clean it) and, for some hearing aids, to make
programme button and/or volume control changes. Some people
find some of these things difficult.
How the intervention might work
Bilateral hearing aids
In normal hearing people, there is general benefit in having two
ears rather than one. A binaural system enables the listener to
determine from which side the sound is coming (lateralisation).
This allows the head to be turned towards the sound source and,
as a result, the source of the sound can be localised. This helps a
listener when attending to specific sounds, for example speech in
the presence of background noise (Bronkhorst 2015).
In the light of this, it is easy to assume that patients with binaural
hearing aids will be able to function more ’normally’ than those
with only one aid. However, as we mention above, amplification
does not produce ’normal’ hearing and those processes that pro-
duced a patient’s sensorineural hearing loss (especially ageing) may
also impact on the way sound is processed and understood.
Possible benefits of bilateral amplification include the following:
• An improved ability to localise sound.
• So-called ’binaural loudness summation’, where an
equivalent sound pressure level is perceived as louder when
presented binaurally.
• The assurance of better-ear listening. In some situations,
one of the ears will be presented with a clearer signal of interest;
having both ears aided theoretically allows patients to take
advantage of all situations.
• Some hearing aid users suffer from ear infections and
related problems, requiring them to leave an aid out of the
affected ear for several days or weeks. Having the option to use
aids in both ears can be helpful in these circumstances.
On the other hand, a potential disadvantage of binaural aiding is
’binaural interference’, where the patient’s speech recognition is
poorer when presented in both ears rather than just one.
In summary, whilst there are theoretical reasons why binaural aids
might work better than a single aid, based on an idea that this
restores a patient to a more ’normal’ situation, there remains un-
certainty about this. There are also several practical issues relating
to the use of two aids rather than one that may also impact on the
outcomes of binaural aiding.
Why it is important to do this review
The existence of two main strategies for fitting hearing aids (bi-
lateral versus unilateral) for patients with bilateral hearing loss has
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arisen due to uncertainty about the relative benefits to patients and
cost-effectiveness. There is a lack of understanding of the factors
leading to non-use of aids. This is true of those who use a single
aid as well as those with two aids (McCormack 2013).
These fitting strategies may lead to one of several outcomes:
• abandonment of the use of one or both hearing aids
altogether;
• satisfaction and continued use of one or both aids;
• continued use of one aid but abandonment of the second; or
• a desire to try a second aid by those fitted with only one.
Finally, whether the use of one or two hearing aids prevails depends
on many patient characteristics (audiometric, lifestyle and expec-
tations), the method of hearing aid fitting and the rehabilitative
approach. The interplay of these factors is not well understood.
In the absence of strong evidence of the prognostic factors that
can specifically predict patient preference and outcomes, evidence
from randomised controlled trials on the relative effectiveness of
bilateral versus unilateral fitting is important to guide practice.
We have not identified any previous systematic review therefore a
Cochrane Review to evaluate the effects of unilateral versus bilat-
eral hearing aids for bilateral hearing impairment is warranted.
O B J E C T I V E S
To assess the effects of bilateral versus unilateral hearing aids in
adults with a bilateral hearing impairment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs). This includes:
• parallel-group study designs, where patients are randomised
to unilateral or bilateral aids; or
• cross-over study designs for the order of fitting of unilateral/
bilateral aids for each patient; or
• cluster-randomised trials, where randomisation is done by
practice or setting (the number of randomised groups must be
more than two);
• quasi-randomised trials, because only a small number of
trials is expected.
Types of participants
We will include studies if the participants meet the following cri-
teria:
• adults (over 18 years);
• with a bilateral hearing impairment and both ears suitable
for hearing aids.
We will exclude studies from the review if a majority of the partic-
ipants have one or more of the following characteristics:
• although asymmetric hearing impairment will not be
excluded, if a patient has one ear that is audiometrically normal
or one ear that has a profound or total loss conventional hearing
aids are not appropriate for them;
• active external or middle ear disease;
• previous experience of using a hearing aid.
Types of interventions
The comparison of interest is:
• fitting of two versus one ear-level acoustic hearing aids.
We will exclude implants, body-worn aids and bone-conduction
hearing aids.
We will apply no minimum duration of use or follow-up as an in-
clusion criterion, but we will consider these as part of the GRADE
evidence evaluation for indirectness of evidence.
Types of outcome measures
We will analyse the following outcomes in the review, but we will
not use them as a basis for including or excluding studies.
Primary outcomes
• Patient preference for unilateral versus bilateral aids.
• Hearing-specific health-related quality of life (e.g. Hearing
Handicap Inventory for the Elderly (HHIE), Hearing Handicap
Inventory for Adults (HHIA), Auditory Disability Preference -
Visual Analogue Scale (ADPI-VAS), Quantified Denver Scale of
communication (QDS), Device Orientated Subjective Outcome
Scale)*.
• Adverse effects (pain, infection).
Secondary outcomes
• Usage of hearing aids (e.g. data logging, battery
consumption) for the duration of the trial (Laplante-Levesque
2014).
• Health-related quality of life (Health Utilities Index Mark 3
(HUI-3), the Glasgow Benefit Inventory (GBI), EQ-5D, SF-36,
the World Health Organization (WHO) Disability Assessment
Schedule (WHO-DAS), Self Evaluation of Life Function
(SELF)*.
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• Listening ability (e.g. Abbreviated Profile of Hearing Aid
Benefit (APHAB), Speech, Spatial and Qualities of Hearing Scale
(SSQ), Glasgow Hearing Aid Benefit profile)*.
• Audiometric benefit measured as binaural loudness
summation.
• Outcome reported by carer or ’communication partner’**.
• Annoyance, measured using patient-reported outcome
measures**.
• Sound localisation as measured by laboratory tests**.
• Speech in noise detection as measured by laboratory tests**.
* For the generic health-related quality of life instruments, only
the HUI-3 and the Glasgow Benefit Inventory (GBI) are expected
to have the sensitivity to distinguish the effectiveness of hearing
aids. It will be essential that there is supporting evidence that ques-
tionnaires chosen to measure an outcome have been shown to be
responsive to the provision of hearing aids and have the potential
to differentiate between the benefits of binaural versus monaural
fitting of aids. However, due to the lack of known validated ques-
tionnaires for this purpose, we will collect data from any question-
naire not specified above if relevant or validated.
** These additional outcomes were included as part of a collabo-
ration with a NICE guideline committee and will not be included
in the ’Summary of findings’ table of this review.
Search methods for identification of studies
The Cochrane ENT Information Specialist, in conjunction with
theNICE Information Specialist, will conduct systematic searches
for randomised controlled trials and controlled clinical trials.
There will be no language, publication year or publication status
restrictions. We may contact original authors for clarification and
further data if trial reports are unclear and we will arrange trans-
lations of papers where necessary.
Electronic searches
Published, unpublished and ongoing studies will be identified by
searching the following databases from their inception:
• the Cochrane Register of Studies ENT Trials Register
(search to date);
• the Cochrane Central Register of Controlled Trials
(CENTRAL, current issue);
• Epub Ahead of Print, In-Process & Other Non-Indexed
Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
(1946 to date);
• Ovid EMBASE (1974 to date);
• EBSCO CINAHL (1982 to date);
• LILACS (search to date);
• KoreaMed (search to date);
• Web of Knowledge, Web of Science (1945 to date);
• ClinicalTrials.gov, www.clinicaltrials.gov (search via the
Cochrane Register of Studies to date);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (search to date);
• Google Scholar (search to date).
The subject strategies for databases will be modelled on the search
strategy designed for Ovid MEDLINE, Ovid Embase and CEN-
TRAL in Appendix 1. Where appropriate, these will be com-
bined with subject strategy adaptations of the highly sensitive
search strategy designed by Cochrane for identifying randomised
controlled trials and controlled clinical trials (as described in the
Cochrane Handbook for Systematic Reviews of Interventions Version
5.1.0, Box 6.4.b. (Handbook 2011)).
Searching other resources
We will scan the reference lists of identified publications for ad-
ditional trials and contact trial authors if necessary. In addition,
the Information Specialists will search Ovid MEDLINE, Ovid
Embase and theCochrane Library to retrieve existing systematic re-
views relevant to this systematic review, so that we can scan their
reference lists for additional trials.
Data collection and analysis
Selection of studies
At least two authors will independently screen the titles and ab-
stracts of the papers found by the searches against the criteria for
inclusion. We will then retrieve and independently review the full
text of the potentially eligible papers to determine if they meet the
inclusion criteria for the review. We will resolve any differences by
discussion and consensus, with the involvement of a third author
for clinical or methodological input.
Data extraction and management
At least two authors will independently extract the data from each
trial using a standardised data extraction form (Appendix 2). If any
essential data aremissing from a study then one author will contact
the authors of the papers to request the additional information.
We will try to identify multiple publications for included studies
and, if a study has more than one publication, we will retrieve all
publications to ensure complete extraction of data. If differences
are found between publications of a study, we will contact the
original authors for clarification. We will use data from the main
paper(s) if no further information is found.
Where there are discrepancies in the data extracted by different
review authors, we will check these against the original reports
and resolve differences by discussion and consensus, with the in-
volvement of a third author or a methodologist where appropriate.
We will contact the original study authors for clarification or for
missing data whenever possible.
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For each trial we will document the following information:
• Methods: study design (cross-over, parallel etc.),
randomisation method, unit of randomisation, blinding method,
duration of follow-up.
• Participants: setting, number of participants entered and
analysed, age and sex, inclusion and exclusion criteria, levels of
hearing impairment.
• Type of intervention: type of hearing aids fitted during the
study, duration of each intervention, use of additional
intervention, details of model, type of mould used and fitting
strategy. We will record the rehabilitation strategy used (such as
the ability to position the aid and mould in the ear and to use the
controls).
• Outcomes: assessment method, time point of data
collection.
• Funding sources and declarations of interest.
In addition,wewill also extract baseline information on prognostic
factors (often called ’predictors’ in trials) or effect modifiers that
may affect preferences and outcomes of the study. For this review,
this includes:
• levels or severity of hearing impairment;
• presence of asymmetric hearing loss;
• whether participants had previous experience of hearing aid
use;
• cognitive impairment;
• visual impairment;
• presence of tinnitus.
For the outcomes of interest to the review, we will extract the
findings of the studies on an available case analysis basis; i.e. we
will include data from all patients available at the time points
based on the treatment randomisedwhenever possible, irrespective
of compliance or whether patients had received the treatment as
planned.
In addition to extracting pre-specified information about study
characteristics and aspects of methodology relevant to risk of bias,
we will extract the following summary statistics for each trial and
each outcome:
• For continuous data: the mean values, standard deviations
and number of patients for each treatment group. We will
prioritise using change from baseline data whenever available.
Where change data are not available, we will use the mean and
standard deviation of each group at the end of the study. We will
analyse data from measurement scales as continuous data.
• For binary data: the numbers of participants experiencing
an event and the number of patients assessed at the time point.
• For ordinal scale data: if the data appear to be approximately
normally distributed or if the analysis that the investigators
performed suggests parametric tests were appropriate, then we
will treat the outcome measures as continuous data. Alternatively,
if data are available, we may convert into binary data.
Where studies report data at multiple time points, we will only
extract the longest available data or end of the study data.
Assessment of risk of bias in included studies
GGB and PH will undertake assessment of the risk of bias of
the included trials independently, with the following taken into
consideration, as guided by theCochrane Handbook for Systematic
Reviews of Interventions (Handbook 2011):
• sequence generation;
• allocation concealment;
• blinding;
• incomplete outcome data;
• selective outcome reporting; and
• other sources of bias (validity and sensitivity of
questionnaires and measurement methods used to measure the
outcomes).
We will use the Cochrane ’Risk of bias’ tool in RevMan 5.3 (
RevMan 2014), which involves describing each of these domains
as reported in the trial and then assigning a judgement about the
adequacy of each entry: ’low’, ’high’ or ’unclear’ risk of bias. For
other sources of bias, we will only consider the issue of validity
and sensitivity of questionnaires as a high risk of bias if there is
evidence or a strong rationale to believe that the lack of sensitivity
will bias the results towards ’no difference’, or the type of measure
is unfairly favourable/unfavourable to either of the treatments.
We will revisit and discuss disagreements with all authors until
consensus is reached.
Measures of treatment effect
Wewill summarise dichotomous data as risk ratios (RR) with 95%
confidence intervals (95% CI). For the key outcomes that we will
present in the ’Summary of findings’ table, we will also express
the results as absolute numbers based on the pooled results and
compared to the assumed risk. We may also calculate the num-
ber needed to treat to benefit (NNTB) using the pooled results.
The assumed baseline risk is typically either (a) the median of the
risks of the control groups in the included studies, this being used
to represent a ’medium-risk population’ or, alternatively, (b) the
average risk of the control groups in the included studies is used
as the ’study population’ (Handbook 2011). If a large number of
studies are available, and where appropriate, we may also present
additional data based on the assumed baseline risk in (c) a low-
risk population and (d) a high-risk population.
For continuous outcomes, we will summarise the treatment effect
as the mean difference (MD) with 95% CI or as the standardised
mean difference (SMD) with 95% CI if different scales have been
used to measure the same outcome. We will provide a clinical
interpretation of the SMD values.
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We will dichotomise or analyse ordinal data as a continuous out-
come, depending on the outcome and whether the scale can be
expected to be normally distributed.
Unit of analysis issues
Cross-over studies
In addition to simple parallel randomised controlled trials (where
the unit of randomisation is at the individual level), another pos-
sible design is a cross-over trial where patients are randomised to
different fitting arrangements during different phases of the trial.
If cross-over studies are found and included, our analyses will take
into account the ’paired’ nature of the data across different phases
whenever possible (Elbourne 2002). If these data are not available,
we will analyse only the first phase of the study. By analysing only
the first phase, carry-over effects are avoided.
If both of the above options are unavailable, we will consider using
the data at the end of the trial and note the risk of bias. Since
this is a stable condition, we do not expect a patient’s condition to
fluctuate and hearing aids will only have an effect while they are
in use. Any ’cross-over effect’ is likely to be due to adaptation and
experience of using of hearing aids. Using the end of study data is
also reflective of clinical practice protocols where patients may be
started with one or two hearing aids fitted and then try a different
combination.
Cluster-randomised studies
For cluster-randomised trials, where patients may be randomised
to either unilateral or bilateral fitting depending on the location
or unit of practice, the unit of randomisation will be the unit or
practice rather than the individual. For these designs, we will use
the approximate analyses detailed in Chapter 16 of the Cochrane
Handbook for Systematic Reviews of Interventions to either inflate the
standard error or calculate the effective sample sizes (Handbook
2011).
Dealing with missing data
To obtain any missing data we will make efforts to contact the
corresponding author to request this. In the event of missing data
we will perform an available case analysis.
If standard deviation data are not available, we will approxi-
mate these using the standard estimation methods from P val-
ues, standard errors or 95% CIs, if these are reported, as detailed
in theCochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011). If it is impossible to estimate these, we will
contact the study authors.
Apart from imputations for missing standard deviations, we will
conduct no other imputations. We will extract and analyse all data
using the available case analysis method.
Assessment of heterogeneity
Wewill assess clinical heterogeneity (whichmay be present even in
the absence of statistical heterogeneity) by examining the included
studies for potential differences between them in the types of par-
ticipants recruited, interventions or controls used and outcomes
measured.
We will assess statistical heterogeneity by visually inspecting the
forest plots and considering the Chi2 test (with the threshold for
significant heterogeneity being an associated P value below 0.1).
Wewill also express heterogeneity in terms of the I2 statistic, which
calculates the percentage of variability that is due to heterogeneity
rather than chance with low, medium and high ranges of 20% to
40%, 41% to 60% and 61% to 100%, respectively (Handbook
2011).
Assessment of reporting biases
Wewill assess reporting bias as between-study publication bias and
within-study outcome reporting bias.
Outcome reporting bias (within-study reporting bias)
We will assess within-study reporting bias by comparing the out-
comes reported in the published report against the study protocol,
whenever this can be obtained. If the protocol is not available, we
will compare the outcomes reported to those listed in the methods
section. If results are mentioned but not reported adequately in a
way that allows analysis (e.g. the report only mentions whether the
results were statistically significant or not), bias in a meta-analysis
is likely to occur. We will seek further information from the study
authors. If no further information can be found, we will note this
as being a ’high’ risk of bias. Quite often there will be insufficient
information to judge the risk of bias; we will note this as an ’un-
clear’ risk of bias (Handbook 2011).
Publication bias (between-study reporting bias)
We will assess funnel plots if sufficient trials (more than 10) are
available for an outcome. If we observe asymmetry of the funnel
plot, wewill conduct more formal investigation using themethods
proposed by Egger 1997.
Data synthesis
We will conduct all meta-analyses using Review Manager 5.3 (
RevMan 2014). For dichotomous data, we plan to analyse treat-
ment differences as a risk ratio (RR) calculated using the Mantel-
Haenszel method. We will analyse time-to-event data using the
generic inverse variance method.
For continuous outcomes, if all the data are from the same scale, we
may poolmean values obtained at follow-upwith change outcomes
and report this as a MD. However, if the SMD has to be used as
an effect measure, we will not pool change and endpoint data.
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When statistical heterogeneity is low, random-effects versus fixed-
effect methods yield trivial differences in treatment effects. How-
ever, when statistical heterogeneity is high, the random-effects
method provides a more conservative estimate of the difference.
Subgroup analysis and investigation of heterogeneity
A number of factors could affect the relative benefit of binaural
versus monaural hearing aids. If heterogeneity is detected, we will
assess this using the following subgroup analyses, including:
• type of hearing aid;
• age;
• sex;
• severity of hearing loss - degree of hearing loss will be based
on the better ear hearing threshold average as classified earlier;
• asymmetry of loss;
• cognitive impairment;
• visual impairment;
• presence of tinnitus with hearing loss;
• first time users of hearing aid.
We will conduct some subgroup analyses regardless of whether
statistical heterogeneity is observed, as these are widely suspected
to be potential effectmodifiers. For this review, this will be the type
of hearing aid. We will present the main analyses of this review
according to type of hearing aid.Wewill present all other subgroup
analysis results in tables.
When studies have a mixed group of patients, we will analyse the
study as one of the subgroups (rather than as a mixed group) if
more than 80% of patients belong to one category.
Sensitivity analysis
We will carry out sensitivity analyses to determine whether the
findings are robust to the decisions made in the course of identi-
fying, screening and analysing the trials. We plan to conduct sen-
sitivity analysis for the following factors, whenever possible:
• impact of model chosen: fixed-effect versus random-effects
model;
• risk of bias of included studies: excluding studies with high
risk of bias (we define these as studies that have a high risk of
allocation concealment bias and a high risk of attrition bias
(overall loss to follow-up of > 20%, differential follow-up
observed);
• how outcomes were measured: we will investigate the
impact of including data where the validity of the measurement
is unclear.
If any of these investigations finds a difference in the size of the
effect or heterogeneity, we will mention this in the ’Effects of
interventions’ section.
GRADE and ’Summary of findings’ table
Two authors will independently use the GRADE approach to rate
the overall quality of evidence using GRADEpro GDT (https://
gradepro.org/). The quality of evidence reflects the extent towhich
we are confident that an estimate of effect is correct and we will
apply this in the interpretation of results. There are four possible
ratings: high, moderate, low and very low. A rating of high quality
of evidence implies that we are confident in our estimate of effect
and that further research is very unlikely to change our confidence
in the estimate of effect. A rating of very low quality implies that
any estimate of effect obtained is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision; and
• publication bias.
For this review, we have identified the duration of use of hearing
aids before outcome assessment as being important, as it will take
some time before patients can adjust and fully benefit from the
devices fitted. Therefore, for any outcomes where the duration of
use is less than eight weeks, we will downgrade the evidence for
indirectness. We will also consider downgrading in cases where the
technology used in the hearing aids used in the study is no longer
reflective of currently available hearing aids.
We will include a ’Summary of findings’ table, constructed ac-
cording to the recommendations described in Chapter 10 of
the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011). We will include the following outcomes in the
’Summary of findings’ table:
• Patient preference for unilateral versus bilateral aids.
• Hearing-specific health-related quality of life.
• Adverse effects (pain, infection).
• Usage of hearing aids (e.g. data logging, battery
consumption) for the duration of the trial.
• Health-related quality of life.
• Listening ability.
• Audiometric benefit measured as binaural loudness
summation.
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A P P E N D I C E S
Appendix 1. Draft search strategies
MEDLINE (Ovid) Embase (Ovid) CENTRAL
1 exp Hearing Loss/
2 (hearing adj2 (loss* or impair* or partial*
or deficit* or deteriorat* or degenerat* or
diminish* or difficult* or disabilit* or hard
or one side* or unilateral)).ti,ab
3 deaf*.ti,ab.
4 (hypoacus* or presbycus* or presbyacus*
or sociocus* or nosocus* or anacus*).ti,ab
5 Persons With Hearing Impairments/
6 or/1-5
7 letter/
8 editorial/
9 news/
10 exp historical article/
11 Anecdotes as Topic/
12 comment/
13 case report/
14 (letter or comment*).ti.
15 or/7-14
16 randomized controlled trial/ or ran-
dom*.ti,ab.
17 15 not 16
18 animals/ not humans/
19 Animals, Laboratory/
20 exp animal experiment/
21 exp animal model/
22 exp Rodentia/
23 (rat or rats or mouse or mice).ti.
24 or/17-23
25 6 not 24
26 Hearing Aids/
27 “Correction of Hearing Impairment”/is
[Instrumentation]
28 (hearing adj (aid* or instrument*)).ti,
ab.
29 (ear mold* or earmold* or ear mould*
or earmould* or amplif*).ti,ab
30 or/26-29
31 (contralateral or bilateral* or binaural
or unilateral* or monoaural or (bi adj3 lat-
eral*) or (uni adj3 lateral*) or bimodal).ti,
ab
32 ((both or two or one or left or right or
1 exp *hearing impairment/
2 (hearing adj2 (loss* or impair* or partial*
or deficit* or deteriorat* or degenerat* or
diminish* or difficult* or disabilit* or hard
or one side* or unilateral)).ti,ab
3 deaf*.ti,ab.
4 (hypoacus* or presbycus* or presbyacus*
or sociocus* or nosocus* or anacus*).ti,ab
5 or/1-4
6 letter.pt. or letter/
7 note.pt.
8 editorial.pt
9 case report/ or case study/
10 (letter or comment*).ti.
11 or/6-10
12 randomized controlled trial/ or ran-
dom*.ti,ab.
13 11 not 12
14 animals/ not humans/
15 nonhuman/
16 exp animal experiment/
17 exp Experimental Animal/
18 animal model/
19 exp Rodent/
20 (rat or rats or mouse or mice).ti.
21 or/13-20
22 5 not 21
23 Hearing Aid/
24 (hearing adj (aid* or instrument*)).ti,
ab.
25 (ear mold* or earmold* or ear mould*
or earmould* or amplif*).ti,ab
26 or/23-25
27 (contralateral or bilateral* or binaural
or unilateral* or monoaural or (bi adj3 lat-
eral*) or (uni adj3 lateral*) or bimodal).ti,
ab
28 ((both or two or one or left or right or
single or double) adj3 (side* or ear or ears
or fitting*)).ti,ab
29 27 or 28
30 26 and 29
#1 [mh “hearing loss”]
#2 (hearing near/2 (loss* or impair* or par-
tial* or deficit* or deteriorat* or degenerat*
or diminish* or difficult* or disabilit* or
hard or one side* or unilateral)):ti,ab
#3 deaf*:ti,ab
#4 (hypoacus* or presbycus* or presbyacus*
or sociocus* or nosocus* or anacus*):ti,ab
#5 [mh ˆ“persons with hearing impair-
ments”]
#6 {or #1-#5}
#7 [mh ˆ“Hearing Aids”]
#8 MeSH descriptor: [Correction of Hear-
ing Impairment] this term only and with
qualifier(s): [Instrumentation - IS]
#9 (hearing next (aid* or instrument*)):ti,
ab
#10 (ear nextmold* or earmold* or ear next
mould* or earmould* or amplif*):ti,ab
#11 {or #7-#10}
#12 (contralateral or bilateral* or binaural
or unilateral* or monoaural or (bi near/3
lateral*) or (uni near/3 lateral*) or bimodal)
:ti,ab
#13 ((both or two or one or left or right
or single or double) near/3 (side* or ear or
ears or fitting*)):ti,ab
#14 #12 or #13
#15 #11 and #14
#16 ((both or two or one or left or right
or single or double) near/3 (aid* or instru-
ment*)):ti,ab
#17 #15 or #16
#18 #6 and #17
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(Continued)
single or double) adj3 (side* or ear or ears
or fitting*)).ti,ab
33 31 or 32
34 30 and 33
35 ((both or two or one or left or right or
single or double) adj3 (aid* or instrument*)
).ti,ab
36 34 or 35
37 25 and 36
38 randomized controlled trial.pt.
39 controlled clinical trial.pt.
40 randomi#ed.ti,ab.
41 placebo.ab.
42 randomly.ti,ab.
43 Clinical Trials as topic.sh.
44 trial.ti
45 or/38-44
46 37 and 45
31 ((both or two or one or left or right or
single or double) adj3 (aid* or instrument*)
).ti,ab
32 30 or 31
33 22 and 32
34 random*.ti,ab.
35 factorial*.ti,ab.
36 (crossover* or cross over*).ti,ab.
37 ((doubl* or singl*) adj blind*).ti,ab.
38 (assign* or allocat* or volunteer* or
placebo*).ti,ab.
39 crossover procedure/
40 single blind procedure/
41 randomized controlled trial/
42 double blind procedure/
43 or/34-42
44 33 and 43
Appendix 2. Data extraction form
REF ID: Study title:
Date of extraction: Extracted by:
General comments/notes (internal for discussion):
FLOW CHART OF TRIAL:
Group A
(Intervention)
Group B
(Comparison)
No of people screened
No. of participants randomised - all
No. randomised to each group
No. receiving treatment as allocated
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(Continued)
No. not receiving treatment as allocated
- Reason 1
- Reason 2
No. dropped out
(no available follow-up data for any out-
come)
No. excluded from analysis1 (for all out-
comes)
- Reason 1
- Reason 2
1This should be the people who received the treatment and were therefore not considered ‘dropouts’ but were excluded from all analyses
(e.g. because the data could not be interpreted or the outcome was not recorded for some reason)
Information to go into ’Characteristics of included studies’ table:
Methods X arm, double/single/non-blinded, [multicentre] parallel-group/cross-over/cluster-RCT, with x duration
of treatment and x duration of follow-up
Participants Location: country, no. of sites etc.
Setting of recruitment and treatment:
Sample size:
• Number randomised: x in intervention, y in comparison
• Number completed: x in intervention, y in comparison
Participant (baseline) characteristics:
• Age:
• Gender:
• Main diagnosis: [as stated in paper]
Other important effect modifiers:
• Hearing loss status:
• Degree of asymmetry:
Inclusion criteria:
Exclusion criteria:
Interventions Intervention (n = x): (hearing aid name, type of hearing aid, how this was fitted, hearing aid style, whether
volume control is allowed)
Comparator group (n = y):
Use of additional interventions (common to both treatment arms):
Outcomes1 Outcomes of interest in this review
1. Hearing-specific health-related quality of life
• Hearing Handicap Inventory for the Elderly (HHIE) or HHI for Adults (HHIA)
• Quantified Denver Scale of Communication (QDS)
• Auditory Disability Preference - Visual Analogue Scale (ADPI-VAS)
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(Continued)
• Device Orientated Subjective Outcome Scale
• Any questionnaire not specified above that is relevant
2. Listening ability
• Abbreviated Profile of Hearing Aid Benefit (APHAB)
• Speech, Spatial and Qualities of Hearing (SSQ)
• Glasgow Hearing Aid Benefit Profile (GHABP) disability subscale
• Any questionnaire not specified above that is relevant
3. Adverse effects: pain, infection, etc.
4. Patient preference
Secondary outcomes/important outcomes
5. Outcomes reported by carer or ’communication partner’ [add information on how this was mea-
sured]
6. Usage of hearing aids [add information on how this was measured]
7. Health-related quality of life (generic scale)
• Health Utilities Index Mark 3 (HUI-3)
• EQ-5D
• SF-36
• Glasgow Benefit Inventory (GBI)
• WHO Disability Assessment Schedule (WHO-DAS)
• Self-Evaluation of Life Function (SELF)
• Any questionnaire mot specified above that is relevant
-------------------------------------------------------------------------------
8. Annoyance scale in patient-reported outcomemeasures [add information on how this was measured]
9. Sound localisation as measured by laboratory tests [add information on how this was measured]
10. Speech in noise detection as measured by laboratory tests [add information on how this was
measured]
Funding sources “No information provided”/“None declared”/State source of funding
Declarations of interest “No information provided”/“None declared”/State conflict
Notes
1DELETE all the outcomes that have not been reported in the study, leaving behind only the outcomes that are reported by the study.
FINDINGS OF STUDY
CONTINUOUS OUTCOMES
Results (continuous data table) Results (continuous
Outcome Group A - Bilateral Group B - Unilateral Other summary stats/Notes
Mean SD N Mean SD N Mean difference (95% CI), P values etc.
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(Continued)
Hearing-spe-
cific health-
related qual-
ity of life
• Hearing
Handicap
Inventory for
the Elderly
(HHIE) or
HHI for
Adults
(HHIA)
• Quantified
Denver Scale
of Communi-
cation (QDS)
• Auditory
Disability
Preference -
Visual
Analogue
Scale (ADPI-
VAS)
• Device
Orientated
Subjective
Outcome
Scale
Listening
ability
• Abbreviated
Profile of
Hearing Aid
Benefit
(APHAB)
• Speech,
Spatial and
Qualities of
Hearing
(SSQ)
• Glasgow
Hearing Aid
Benefit Profile
(GHABP)
disability
subscale
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(Continued)
Patient pref-
er-
ence (add in-
formation on
how this was
recorded)
Us-
age of hearing
aids (add in-
formation on
how this was
recorded)
Health-re-
lated quality
of life (generic
scale)
• Health
Utilities Index
Mark 3
(HUI-3)
• EQ-5D
• SF-36
• Glasgow
Benefit
Inventory
(GBI)
• WHO
Disability
Assessment
Schedule
(WHO-DAS)
• Self-
Evaluation of
Life Function
(SELF)
• Any
questionnaire
mot specified
above that is
relevant
Outcomes re-
ported by
carer or ’com-
munication
partner’
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(Continued)
Sound locali-
sa-
tion as mea-
sured by labo-
ratory tests
Speech
in noise detec-
tion as mea-
sured by labo-
ratory tests
Comments: Comments:
Appendix 3. ’Risk of bias’ table template
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High/unclear/low risk Quote:
Comment:
Allocation concealment (selection bias) High/unclear/low risk Quote:
Comment:
Blinding of participants and personnel
(performance bias)
High/unclear/low risk Quote:
Comment:
Blinding of outcome assessment (detection
bias)
High/unclear/low risk Quote:
Comment:
Incomplete outcome data (attrition bias) High/unclear/low risk Quote:
Comment:
Selective reporting (reporting bias) High/unclear/low risk Quote:
Comment:
Other bias High/unclear/low risk Quote:
Comment:
Other bias: insensitive/non-validated in-
strument?
High/unclear/low risk Quote:
Comment:
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George Browning: conceiving, designing and co-ordinating the review, providing a clinical perspective, writing the protocol.
Patrick Howell: providing a clinical perspective, writing the protocol.
William MWhitmer: designing the review, providing a clinical perspective, writing the protocol.
Saoussen Ftouh: providing a methodological perspective, writing the protocol.
Lee Yee Chong: providing a methodological perspective, writing the protocol.
Graham Naylor: providing a clinical perspective, writing the protocol, providing general advice on the review.
D E C L A R A T I O N S O F I N T E R E S T
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Patrick Howell: none known.
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